PMID- 30266573
OWN - NLM
STAT- MEDLINE
DCOM- 20181121
LR  - 20181121
IS  - 1090-2449 (Electronic)
IS  - 0014-4894 (Linking)
VI  - 195
DP  - 2018 Dec
TI  - Prophylactic treatment of L-Arg improves malaria outcomes by regulating host 
      immune responses during Plasmodium yoelii 17XL infection.
PG  - 1-7
LID - S0014-4894(17)30256-4 [pii]
LID - 10.1016/j.exppara.2018.09.013 [doi]
AB  - L-arginine (L-Arg), the precursor of nitric oxide (NO), plays multiple, important 
      roles in nutrient metabolism and immune regulation. Hypoargininemia is one of the 
      distinctive features of malaria patients in endemic areas. To understand the 
      immunoregulatory function of L-Arg in malaria, we investigated the effects of 
      L-Arg, pre- or/and post-treatment, on the cellular/humoral immune response during 
      Plasmodium yoelii 17XL (P.y17XL) infection in DBA/2 mice. Populations of splenic 
      CD4(+)T-bet(+)IFN-gamma(+) T cells (Th1), F4/80(+) macrophages, 
      CD4(+)GATA-3(+)IL-4(+) T cells (Th2), B220(+)CD138(+) plasmacytes and 
      antibody-producing cells (IgG(+)/IgG1(+)-plasma cells) were assessed by flow 
      cytometry. Pro-inflammatory cytokines and antibodies (IgG and IgG1) were 
      quantified by immunoassays. We found that treatment with L-Arg significantly 
      decreased parasitemia and shortened disease duration. Prophylactic treatment with 
      L-Arg promotes an enhanced Th1 cell response during the early stages of P.y17XL 
      infection, and treatment with L-Arg in the course of infection facilitates the 
      later humoral immune response. Our findings suggest that treatment with L-Arg may 
      decrease parasite burden and control the host's susceptibility to parasite 
      synchronously by regulating host immune responses against P.y17XL, producing 
      better outcomes for malaria infection. This implies that the supplementation of 
      L-Arg may be a promising adjunctive therapy to reduce malaria-associated 
      mortality in endemic areas.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Wang, Qiubo
AU  - Wang Q
AD  - Department of Immunology, College of Basic Medical Sciences, China Medical 
      University, Shenyang, Liaoning Province, PR China.
FAU - Feng, Yonghui
AU  - Feng Y
AD  - Department of Laboratory Medicine, The First Hospital of China Medical 
      University, Shenyang, Liaoning, PR China.
FAU - Sun, Xiaodan
AU  - Sun X
AD  - Department of Immunology, College of Basic Medical Sciences, China Medical 
      University, Shenyang, Liaoning Province, PR China.
FAU - Pang, Wei
AU  - Pang W
AD  - Department of Immunology, College of Basic Medical Sciences, China Medical 
      University, Shenyang, Liaoning Province, PR China.
FAU - Fu, Weixin
AU  - Fu W
AD  - Science Experiment Center of China Medical University, Shenyang, Liaoning 
      Province, PR China. Electronic address: wxfu@cmu.edu.cn.
FAU - Cao, Yaming
AU  - Cao Y
AD  - Department of Immunology, College of Basic Medical Sciences, China Medical 
      University, Shenyang, Liaoning Province, PR China. Electronic address: 
      ymcao@cmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20180925
PL  - United States
TA  - Exp Parasitol
JT  - Experimental parasitology
JID - 0370713
RN  - 0 (Antibodies, Protozoan)
RN  - 0 (Immunoglobulin G)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 94ZLA3W45F (Arginine)
SB  - IM
MH  - Animals
MH  - Antibodies, Protozoan/biosynthesis/immunology
MH  - Antibody-Producing Cells/drug effects/immunology
MH  - Arginine/blood/*therapeutic use
MH  - Flow Cytometry
MH  - Immunoglobulin G/biosynthesis/blood
MH  - Interferon-gamma/metabolism
MH  - Malaria/*drug therapy/immunology/prevention & control
MH  - Mice
MH  - Mice, Inbred DBA
MH  - Nitric Oxide/metabolism
MH  - Parasitemia/drug therapy/prevention & control
MH  - Plasmodium yoelii/*immunology
MH  - Th1 Cells/drug effects/immunology
MH  - Th2 Cells/cytology/drug effects/immunology
OTO - NOTNLM
OT  - Antibody
OT  - L-arginine
OT  - Malaria
OT  - P.y17XL
OT  - Th1/Th2 responses
EDAT- 2018/09/30 06:00
MHDA- 2018/11/22 06:00
CRDT- 2018/09/30 06:00
PHST- 2017/05/23 00:00 [received]
PHST- 2018/02/23 00:00 [revised]
PHST- 2018/09/20 00:00 [accepted]
PHST- 2018/09/30 06:00 [pubmed]
PHST- 2018/11/22 06:00 [medline]
PHST- 2018/09/30 06:00 [entrez]
AID - S0014-4894(17)30256-4 [pii]
AID - 10.1016/j.exppara.2018.09.013 [doi]
PST - ppublish
SO  - Exp Parasitol. 2018 Dec;195:1-7. doi: 10.1016/j.exppara.2018.09.013. Epub 2018 
      Sep 25.